Responses
Clinical/translational cancer immunotherapy
Original research
Combination of vasculature targeting, hypofractionated radiotherapy, and immune checkpoint inhibitor elicits potent antitumor immune response and blocks tumor progression
Compose a Response to This Article
Other responses
No responses have been published for this article.
